June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The miRNA451a/ATF2 signal pathway regulates mitochondrial function of RPE in diabetic conditions
Author Affiliations & Notes
  • yan shao
    physiology, OUHSC, Oklahoma city, Oklahoma, United States
    Tianjin medical university eye hospitial, Tianjin, China
  • Lijie Dong
    Tianjin medical university eye hospitial, Tianjin, China
  • Yusuke Takahashi
    physiology, OUHSC, Oklahoma city, Oklahoma, United States
  • Xun Liu
    Tianjin medical university eye hospitial, Tianjin, China
  • Qian Chen
    physiology, OUHSC, Oklahoma city, Oklahoma, United States
  • Xiaorong Li
    physiology, OUHSC, Oklahoma city, Oklahoma, United States
  • Jian-Xing (Jay) Ma
    physiology, OUHSC, Oklahoma city, Oklahoma, United States
    Tianjin medical university eye hospitial, Tianjin, China
  • Footnotes
    Commercial Relationships   yan shao, None; Lijie Dong, None; Yusuke Takahashi, None; Xun Liu, None; Qian Chen, None; Xiaorong Li, None; Jian-Xing (Jay) Ma, None
  • Footnotes
    Support  Natural science foundation of Tianjin, China 15JCQNJ11400
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4035. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      yan shao, Lijie Dong, Yusuke Takahashi, Xun Liu, Qian Chen, Xiaorong Li, Jian-Xing (Jay) Ma; The miRNA451a/ATF2 signal pathway regulates mitochondrial function of RPE in diabetic conditions. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4035.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mitochondrial dysfunction plays a pathogenic role in diabetic retinopathy. The purpose of this study was to explore the role of miRNA451a (miR-451a) in mitochondrial dysfunction induced by diabetes.

Methods : Vitreous and epiretinal membrane samples were collected from 14 patients with proliferative diabetic retinopathy (PDR). The membranes were used for immunolabeling of ki-67 protein and RPE65 protein to identify retinal pigment epithelial cells. The vitreous samples were divided into two groups according to Ki-67 expression. Vitreous miRNA profiles were analyzed using miRNA-specific qPCR microarray. The expression of miR-451a was measured by RT-PCR in DB/DB mice. The expression of miR-451a, was quantified by q-PCR in ARPE-19 cells under diabetic conditions. The potential downstream targets of the miRNA were predicted and confirmed by dual luciferase assay, qRT-PCR and Western blotting. Mitochondrial function changes were measured by Seahorse after transfection of miR-451a mimics and inhibitor into ARPE19 cells.

Results : In proliferative vitreoretinopathy membrane, RPE cells account for 2.57%±3.19%(1.61%-11.11%). Proliferative index (PI) = 2.57%±3.19%(1.61%-11.11%). Some RPE cells were Ki-67-positvie cells. MiRNA-specific qPCR microarray showed that the level of miR-451a was substantially higher from the eye with Ki-67-positive membrane than the eye with Ki-67-negative membrane. The expression of miR-451 in the retina was increased by 4-fold in 6-month-old DB/DB mice, compared to age-matched non-diabetic controls (P=0.03). In ARPE19 cells, high glucose up-regulated miR-451a expression. HNE down-regulated miR-451a expression. Bioinformatic analysis and luciferase assay identified activating transcription factor 2 (ATF2) as a potential target of miR-451a. RT-PCR and Western blotting revealed that overexpression of miR-451a down-regulated the expression of ATF2 (P<0.05). The mitochondrial function was enhanced by miR-451a mimics, while suppressed by inhibitor. The basal oxygen consumption rate (OCR) and maximal OCR in miR-451a overexpression group were significantly higher than control group (P=0.014, 0.015). Under high glucose condition, overexpression of miR-451a enhanced the mitochondrial function.

Conclusions : MiR-451a/ATF2 plays a role in regulation of the mitochondrial function in the RPE, which open new perspectives for the development of effective therapies of PDR.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×